Skip to main content
SpringerLink
Log in

GI-NET: Somatostatin-Analogon verlängert PFS

  • Literatur kompakt_Gastrointestinale Tumoren
  • Published:
Im Focus Onkologie Aims and scope

Somatostatin-Analoga werden oft zur symptomatischen Therapie funktionell aktiver neuroendokriner Tumoren (NET) eingesetzt. Daten zu möglichen antitumoralen Effekten liefert jetzt eine placebokontrollierte Phase-III-Studie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Caplin ME et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-33.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Barbara Kreutzkamp

Authors
  1. Barbara Kreutzkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kreutzkamp, B. GI-NET: Somatostatin-Analogon verlängert PFS. Im Focus Onkologie 17, 25 (2014). https://doi.org/10.1007/s15015-014-1490-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1490-6

Search

Navigation